Gene · 4698
NDUFA5: NADH:ubiquinone oxidoreductase subunit A5
12 sourcesgene-search-2026-11-11-0.2.0
Cite this record
ConductScience Library. NDUFA5: NADH:ubiquinone oxidoreductase subunit A5. Genes, record 4698. Release gene-search-2026-11-11-0.2.0, 11 Nov 2026. https://conductscience.org/library/genes/4698
On this page
Gene
Proteins1
Reviewed human proteins whose Swiss-Prot entry states the gene.
| UniProt entry | Protein | Length | Structures | Gene stated in |
|---|---|---|---|---|
| Q16718 | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 5 | 116 | 7 | Ensembl, GeneID, HGNC |
Source UniProt
Patents26
Patents whose sequence listing contains this protein's exact sequence. A patent can list a sequence without claiming it.
| Publication | Published | SEQ ID NO | Protein | Source |
|---|---|---|---|---|
| JP 2026004568 A | 2026-01-14 | 54924 | Q16718 | Espacenet |
| EP 4650780 A2 | 2025-11-19 | 7206 | Q16718 | Espacenet |
| JP 2025517970 A | 2025-06-12 | 7206 | Q16718 | Espacenet |
| US 11446398 B2 | 2022-09-20 | 55063 | Q16718 | Espacenet |
| JP 2022524081 A | 2022-04-27 | 158034 | Q16718 | Espacenet |
| WO 2020043864 A1 | 2020-03-05 | 1592 | Q16718 | Espacenet |
| JP 2019054813 A | 2019-04-11 | 235359 | Q16718 | Espacenet |
| JP 2017121241 A | 2017-07-13 | 235359 | Q16718 | Espacenet |
| JP 2015516143 A | 2015-06-08 | 235359 | Q16718 | Espacenet |
| US 8586006 B2 | 2013-11-19 | 14700 | Q16718 | Espacenet |
1 to 10 of 26
See all 26 patentsDrugs4
Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.
| Drug | ChEMBL ID | Mechanism | Action | Source |
|---|---|---|---|---|
| ME-344 | CHEMBL5314386 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN | CHEMBL1431 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| METFORMIN HYDROCHLORIDE | CHEMBL1703 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
| NV-128 | CHEMBL3545135 | Mitochondrial complex I (NADH dehydrogenase) inhibitor | INHIBITOR | ChEMBL |
Trials1,218
Trials of those drugs. A trial joins the gene only through a drug that acts on it.
| Trial | Drug | Phase | Results first posted | Source |
|---|---|---|---|---|
| NCT07604870 | METFORMIN | PHASE2 | ClinicalTrials.gov | |
| NCT07604779 | METFORMIN | ClinicalTrials.gov | ||
| NCT07603505 | METFORMIN | PHASE1 | ClinicalTrials.gov | |
| NCT07589387 | METFORMIN | ClinicalTrials.gov | ||
| NCT07588932 | METFORMIN | EARLY_PHASE1 | ClinicalTrials.gov | |
| NCT07585396 | METFORMIN | PHASE2/PHASE3 | ClinicalTrials.gov | |
| NCT07582471 | METFORMIN | ClinicalTrials.gov | ||
| NCT07520110 | METFORMIN | PHASE3 | ClinicalTrials.gov | |
| NCT07516821 | METFORMIN | ClinicalTrials.gov | ||
| NCT07513480 | METFORMIN | ClinicalTrials.gov |
1 to 10 of 1,218
See all 1,218 trialsNIH grants1,242
NIH grants whose papers are about the gene, through NIH's grant-paper links.
| Grant | Title | NDUFA5 papers | Newest fiscal year |
|---|---|---|---|
| P01CA097132 | Sphingolipids in Cancer Biology and Therapy | 11 | 2025 |
| P30AI060354 | Harvard University Center for AIDS Research | 6 | 2025 |
| P30CA138313 | Medical University of South Carolina - Cancer Center Support Grant | 6 | 2025 |
| P30CA008748 | Cancer Center Support Grant | 5 | 2025 |
| P30CA016672 | Cancer Center Support Grant | 5 | 2025 |
| ZIAAI005024 | Design Of Immunogens | 4 | 2025 |
| ZIAAI005095 | HIV Neutralizing Antibodies: Isolation, characterization, and interaction with viral variants | 4 | 2025 |
| P30CA046592 | University of Michigan Rogel Cancer Center Support Grant 2023-2028 | 3 | 2025 |
| T32AI007387 | Multidisciplinary HIV Training Program | 3 | 2025 |
| ZIAAI005023 | Mechanisms Of Humoral Evasion | 3 | 2025 |
1 to 10 of 1,242Source NIH's project files
See all 1,242 nih grantsPapers1,744
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Targeting Ceramide Metabolism to Overcome Osimertinib Resistance in EGFR-mutant Non-Small Cell Lung Cancer: An In Vitro, Network Pharmacology, and In Silico Study. | Anticancer Agents Med Chem | 2026 | 42333846 | PubTator, text mining | PubMed |
| Integrative analysis of bulk and single-nucleus transcriptomes suggests proteostasis- and metabolism-related alterations in the right ventricular outflow tract of non-syndromic Tetralogy of Fallot. | Funct Integr Genomics | 2026 | 42230411 | PubTator, text mining | PubMed |
| Design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazine derivatives as potent SYK inhibitors for solid tumor therapy. | Bioorg Chem | 2026 | 42184580 | PubTator, text mining | PubMed |
| Effect of glycosidic torsional energetics on the conformational properties of polysaccharide chains: a Monte Carlo study. | Carbohydr Res | 2026 | 42097018 | PubTator, text mining | PubMed |
| Bi-allelic variants in NDUFA5 cause a mitochondriopathy with complex I deficiency. | Am J Hum Genet | 2026 | 41916321 | PubTator, text mining | PubMed |
| Comprehensive analysis of gp120 glycosylation to explore differences between transmitter/founder and chronic HIV-1 isolates. | Glycobiology | 2026 | 41885535 | PubTator, text mining | PubMed |
| Investigating Metabolically Altered Pathways in Small Cell Lung Cancer: From RNA Sequencing Analysis to Seahorse-Based Functional Validation. | Methods Protoc | 2026 | 41874163 | PubTator, text mining | PubMed |
| Hyaluronic acid degradation by Purpureocillium lilacinum: biochemical and transcriptomic insights. | Appl Microbiol Biotechnol | 2026 | 41865196 | PubTator, text mining | PubMed |
| Identification of respiratory chain complex I deficiency due to NDUFA5 variants as a novel cause of infantile fatal disease. | Genes Dis | 2026 | 41859003 | PubTator, text mining | PubMed |
| Transcriptomic analysis reveals synaptic dysregulation and mitochondrial dysfunction in autism spectrum disorder. | Brain Behav Immun Health | 2026 | 41799280 | PubTator, text mining | PubMed |
1 to 10 of 1,744
See all 1,744 papersSources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this gene from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/genes/v1/4698
GET https://conductscience.org/api/genes/v1/4698/patents?page=2